Published in J Clin Invest on December 21, 2012
Network-based stratification of tumor mutations. Nat Methods (2013) 3.12
Whole-genome characterization of chemoresistant ovarian cancer. Nature (2015) 3.06
Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun (2013) 2.94
Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes. PLoS One (2014) 1.99
Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. J Natl Cancer Inst (2014) 1.93
Identification of sample annotation errors in gene expression datasets. Arch Toxicol (2015) 1.68
Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples. J Natl Cancer Inst (2014) 1.58
Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients. EMBO Mol Med (2014) 1.51
Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget (2014) 1.47
A collagen-remodeling gene signature regulated by TGF-β signaling is associated with metastasis and poor survival in serous ovarian cancer. Clin Cancer Res (2013) 1.46
Comparison of the Prognostic Utility of the Diverse Molecular Data among lncRNA, DNA Methylation, microRNA, and mRNA across Five Human Cancers. PLoS One (2015) 1.43
Suboptimal cytoreduction in ovarian carcinoma is associated with molecular pathways characteristic of increased stromal activation. Gynecol Oncol (2015) 1.42
Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer. EMBO Mol Med (2013) 1.38
Tumorgrafts as in vivo surrogates for women with ovarian cancer. Clin Cancer Res (2014) 1.35
Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. Nat Med (2016) 1.22
Predicting time to ovarian carcinoma recurrence using protein markers. J Clin Invest (2013) 1.17
Genomic and transcriptomic plasticity in treatment-naive ovarian cancer. Genome Res (2013) 1.15
ARID1A mutations and PI3K/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas. Int J Mol Sci (2013) 1.14
Combined image and genomic analysis of high-grade serous ovarian cancer reveals PTEN loss as a common driver event and prognostic classifier. Genome Biol (2014) 1.11
Comprehensive analysis of lncRNA expression profiles reveals a novel lncRNA signature to discriminate nonequivalent outcomes in patients with ovarian cancer. Oncotarget (2016) 1.11
Treatment options in recurrent ovarian cancer: latest evidence and clinical potential. Ther Adv Med Oncol (2014) 1.05
Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours. Nat Commun (2015) 1.03
In vivo tumor growth of high-grade serous ovarian cancer cell lines. Gynecol Oncol (2015) 1.02
A multivariate approach to the integration of multi-omics datasets. BMC Bioinformatics (2014) 1.01
Comparison of gene expression patterns across 12 tumor types identifies a cancer supercluster characterized by TP53 mutations and cell cycle defects. Oncogene (2014) 0.99
NADPH oxidases: a perspective on reactive oxygen species production in tumor biology. Antioxid Redox Signal (2013) 0.99
Systematic transcriptome analysis reveals tumor-specific isoforms for ovarian cancer diagnosis and therapy. Proc Natl Acad Sci U S A (2015) 0.92
Novel Axl-driven signaling pathway and molecular signature characterize high-grade ovarian cancer patients with poor clinical outcome. Oncotarget (2015) 0.91
Molecular signatures of epithelial ovarian cancer: analysis of associations with tumor characteristics and epidemiologic risk factors. Cancer Epidemiol Biomarkers Prev (2013) 0.91
Prognostic biomarkers in endometrial and ovarian carcinoma. Virchows Arch (2014) 0.90
Más-o-menos: a simple sign averaging method for discrimination in genomic data analysis. Bioinformatics (2014) 0.89
Clinical implications for loss or diminution of expression of Raf-1 kinase inhibitory protein and its phosphorylated form in ductal breast cancer. Am J Cancer Res (2013) 0.88
GRHL2-miR-200-ZEB1 maintains the epithelial status of ovarian cancer through transcriptional regulation and histone modification. Sci Rep (2016) 0.88
Single Gene Prognostic Biomarkers in Ovarian Cancer: A Meta-Analysis. PLoS One (2016) 0.87
Prediction of resistance to chemotherapy in ovarian cancer: a systematic review. BMC Cancer (2015) 0.85
MARCKS contributes to stromal cancer-associated fibroblast activation and facilitates ovarian cancer metastasis. Oncotarget (2016) 0.85
Association between morphologic CT imaging traits and prognostically relevant gene signatures in women with high-grade serous ovarian cancer: a hypothesis-generating study. Radiology (2014) 0.84
Role of the immune system in the peritoneal tumor spread of high grade serous ovarian cancer. Oncotarget (2016) 0.84
A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol (2014) 0.84
Quantitative histology analysis of the ovarian tumour microenvironment. Sci Rep (2015) 0.83
Reactive oxygen species-mediated therapeutic response and resistance in glioblastoma. Cell Death Dis (2015) 0.83
Unique pattern of component gene disruption in the NRF2 inhibitor KEAP1/CUL3/RBX1 E3-ubiquitin ligase complex in serous ovarian cancer. Biomed Res Int (2014) 0.81
Long noncoding RNA expression signature to predict platinum-based chemotherapeutic sensitivity of ovarian cancer patients. Sci Rep (2017) 0.81
Preoperative red cell distribution width and neutrophil-to-lymphocyte ratio predict survival in patients with epithelial ovarian cancer. Sci Rep (2017) 0.81
Elevated AKAP12 in paclitaxel-resistant serous ovarian cancer cells is prognostic and predictive of poor survival in patients. J Proteome Res (2015) 0.81
Identification of a multi-cancer gene expression biomarker for cancer clinical outcomes using a network-based algorithm. Sci Rep (2015) 0.81
Genetic and epigenetic heterogeneity of epithelial ovarian cancer and the clinical implications for molecular targeted therapy. J Cell Mol Med (2016) 0.81
Targeting Stromal-Cancer Cell Crosstalk Networks in Ovarian Cancer Treatment. Biomolecules (2016) 0.80
Migration and invasion is inhibited by silencing ROR1 and ROR2 in chemoresistant ovarian cancer. Oncogenesis (2016) 0.80
RKIP regulates CCL5 expression to inhibit breast cancer invasion and metastasis by controlling macrophage infiltration. Oncotarget (2015) 0.80
Stroma-associated master regulators of molecular subtypes predict patient prognosis in ovarian cancer. Sci Rep (2015) 0.80
Large-scale microarray profiling reveals four stages of immune escape in non-Hodgkin lymphomas. Oncoimmunology (2016) 0.79
Big data and computational biology strategy for personalized prognosis. Oncotarget (2016) 0.79
Risk prediction model for epithelial ovarian cancer using molecular markers and clinical characteristics. J Ovarian Res (2015) 0.79
Identification of AIM2 as a downstream target of JAK2V617F. Exp Hematol Oncol (2016) 0.79
A transcriptome-based global map of signaling pathways in the ovarian cancer microenvironment associated with clinical outcome. Genome Biol (2016) 0.78
On representing the prognostic value of continuous gene expression biomarkers with the restricted mean survival curve. Oncotarget (2015) 0.78
Characteristics of 10-year survivors of high-grade serous ovarian carcinoma. Gynecol Oncol (2016) 0.77
Dimension reduction techniques for the integrative analysis of multi-omics data. Brief Bioinform (2016) 0.77
Similarity and diversity of the tumor microenvironment in multiple metastases: critical implications for overall and progression-free survival of high-grade serous ovarian cancer. Oncotarget (2016) 0.77
CSIOVDB: a microarray gene expression database of epithelial ovarian cancer subtype. Oncotarget (2015) 0.77
Sox2 gene amplification significantly impacts overall survival in serous epithelial ovarian cancer. Reprod Sci (2014) 0.77
Invasion Patterns of Metastatic Extrauterine High-grade Serous Carcinoma With BRCA Germline Mutation and Correlation With Clinical Outcomes. Am J Surg Pathol (2016) 0.77
Human monocytes in the presence of interferons alpha2a and gamma are potent killers of serous ovarian cancer cell lines in combination with paclitaxel and carboplatin. J Interferon Cytokine Res (2014) 0.77
Vascular endothelial growth factor A as predictive marker for mTOR inhibition in relapsing high-grade serous ovarian cancer. BMC Syst Biol (2016) 0.77
Dual mTORC1/2 Inhibition as a Novel Strategy for the Resensitization and Treatment of Platinum-Resistant Ovarian Cancer. Mol Cancer Ther (2016) 0.77
Differential antigen expression profile predicts immunoreactive subset of advanced ovarian cancers. PLoS One (2014) 0.77
Prediction of anti-angiogenesis escape. Gynecol Oncol (2015) 0.76
Epidemiology's continuing contribution to public health: The power of "Then and Now". Am J Epidemiol (2015) 0.76
MAP3K8/TPL-2/COT is a potential predictive marker for MEK inhibitor treatment in high-grade serous ovarian carcinomas. Nat Commun (2015) 0.76
Microarray enriched gene rank. BioData Min (2015) 0.75
Novel Monte Carlo approach quantifies data assemblage utility and reveals power of integrating molecular and clinical information for cancer prognosis. Sci Rep (2015) 0.75
A VEGF-dependent gene signature enriched in mesenchymal ovarian cancer predicts patient prognosis. Sci Rep (2016) 0.75
High-grade serous ovarian cancer 3 years after bilateral salpingectomy: A case report. Mol Clin Oncol (2016) 0.75
Medoidshift clustering applied to genomic bulk tumor data. BMC Genomics (2016) 0.75
Molecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and Treatment. Int J Mol Sci (2016) 0.75
STAT1-associated intratumoural TH1 immunity predicts chemotherapy resistance in high-grade serous ovarian cancer. J Pathol Clin Res (2016) 0.75
Single-sample expression-based chemo-sensitivity score improves survival associations independently from genomic mutations for ovarian cancer Patients. AMIA Jt Summits Transl Sci Proc (2016) 0.75
Association between targeted somatic mutation (TSM) signatures and HGS-OvCa progression. Cancer Med (2016) 0.75
NUAK1 (ARK5) Is Associated with Poor Prognosis in Ovarian Cancer. Front Oncol (2016) 0.75
Dynamic changes of tumor gene expression during repeated pressurized intraperitoneal aerosol chemotherapy (PIPAC) in women with peritoneal cancer. BMC Cancer (2016) 0.75
Subtypes of Ovarian Cancer and Ovarian Cancer Screening. Diagnostics (Basel) (2017) 0.75
A COL11A1-correlated pan-cancer gene signature of activated fibroblasts for the prioritization of therapeutic targets. Cancer Lett (2016) 0.75
Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status. Nat Commun (2016) 0.75
Identification of stably expressed reference small non-coding RNAs for microRNA quantification in high-grade serous ovarian carcinoma tissues. J Cell Mol Med (2016) 0.75
Identification of 42 Genes Linked to Stage II Colorectal Cancer Metastatic Relapse. Int J Mol Sci (2016) 0.75
Comprehensive Cross-Population Analysis of High-Grade Serous Ovarian Cancer Supports No More Than Three Subtypes. G3 (Bethesda) (2016) 0.75
Expression signature distinguishing two tumour transcriptome classes associated with progression-free survival among rare histological types of epithelial ovarian cancer. Br J Cancer (2016) 0.75
A non-negative matrix factorization method for detecting modules in heterogeneous omics multi-modal data. Bioinformatics (2015) 0.75
Single cell sequencing reveals heterogeneity within ovarian cancer epithelium and cancer associated stromal cells. Gynecol Oncol (2017) 0.75
Gynaecological cancer: CLOVAR validates prognostic gene-expression signature. Nat Rev Clin Oncol (2013) 0.75
Molecular integrative clustering of Asian gastric cell lines revealed two distinct chemosensitivity clusters. PLoS One (2014) 0.75
Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer. BMC Med (2017) 0.75
Stem cell systems informatics for advanced clinical biodiagnostics: tracing molecular signatures from bench to bedside. Croat Med J (2013) 0.75
Expression of phosphorylated Akt and hTERT is associated with prognosis of epithelial ovarian carcinoma. Int J Clin Exp Pathol (2015) 0.75
IPI59: An Actionable Biomarker to Improve Treatment Response in Serous Ovarian Carcinoma Patients. Stat Biosci (2016) 0.75
Molecular classification of high grade endometrioid and clear cell ovarian cancer using TCGA gene expression signatures. Gynecol Oncol (2016) 0.75
Identification of common oncogenic and early developmental pathways in the ovarian carcinomas controlling by distinct prognostically significant microRNA subsets. BMC Genomics (2017) 0.75
Early and consistent overexpression of ADRM1 in ovarian high-grade serous carcinoma. J Ovarian Res (2017) 0.75
Expression profiles analysis reveals an integrated miRNA-lncRNA signature to predict survival in ovarian cancer patients with wild-type BRCA1/2. Oncotarget (2017) 0.75
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A (2001) 132.88
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics (2003) 100.88
Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 75.40
A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med (2002) 58.15
Integrated genomic analyses of ovarian carcinoma. Nature (2011) 47.72
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med (2004) 41.02
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet (2005) 29.45
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med (2009) 24.75
Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol (2009) 22.22
Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science (2003) 13.19
The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer (2007) 12.38
Cancer of the ovary. N Engl J Med (2004) 11.21
GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol (2011) 9.60
The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer (2009) 9.01
Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res (2008) 8.17
Molecular signatures database (MSigDB) 3.0. Bioinformatics (2011) 8.08
Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA (2011) 6.81
Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet (2009) 6.65
Retracted An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol (2007) 5.77
Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med (2012) 5.31
Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol (2010) 5.23
Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol (2010) 4.23
A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res (2008) 4.05
Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA (2012) 3.85
Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J Clin Oncol (2008) 3.74
Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol (2010) 3.54
Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clin Cancer Res (2009) 3.45
Suppression of lung adenocarcinoma progression by Nkx2-1. Nature (2011) 3.27
Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res (2005) 2.98
AffyProbeMiner: a web resource for computing or retrieving accurately redefined Affymetrix probe sets. Bioinformatics (2007) 2.93
Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol (2004) 2.91
Notch3 gene amplification in ovarian cancer. Cancer Res (2006) 2.66
Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clin Cancer Res (2005) 2.29
Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis. Oncogene (2009) 2.27
Survival-related profile, pathways, and transcription factors in ovarian cancer. PLoS Med (2009) 1.88
Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol (2010) 1.87
Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clin Cancer Res (2005) 1.86
The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res (2004) 1.65
Gene expression profile for predicting survival in advanced-stage serous ovarian cancer across two independent datasets. PLoS One (2010) 1.58
A prognostic gene expression index in ovarian cancer - validation across different independent data sets. J Pathol (2009) 1.55
Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. Clin Cancer Res (2011) 1.47
ERCC1 and clinical resistance to platinum-based therapy. Clin Cancer Res (2005) 1.41
Mismatch repair and treatment resistance in ovarian cancer. BMC Cancer (2006) 1.07
Unifying gene expression measures from multiple platforms using factor analysis. PLoS One (2011) 1.06
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res (2010) 97.51
Initial sequencing and comparative analysis of the mouse genome. Nature (2002) 96.15
Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 75.40
MicroRNA expression profiles classify human cancers. Nature (2005) 69.12
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet (2011) 59.36
PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet (2003) 53.59
Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science (2007) 51.70
Integrated genomic analyses of ovarian carcinoma. Nature (2011) 47.72
Integrative genomics viewer. Nat Biotechnol (2011) 42.83
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
GenePattern 2.0. Nat Genet (2006) 29.07
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell (2006) 27.36
Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nat Biotechnol (2009) 27.17
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med (2005) 26.35
A comprehensive catalogue of somatic mutations from a human cancer genome. Nature (2009) 24.27
Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform (2012) 23.58
ARACHNE: a whole-genome shotgun assembler. Genome Res (2002) 22.72
GoMiner: a resource for biological interpretation of genomic and proteomic data. Genome Biol (2003) 22.63
Signatures of mutational processes in human cancer. Nature (2013) 21.63
International network of cancer genome projects. Nature (2010) 20.35
Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature (2013) 20.16
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 19.87
Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A (2007) 18.83
Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature (2009) 18.08
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell (2005) 17.41
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev (2007) 17.20
BRAF mutation predicts sensitivity to MEK inhibition. Nature (2005) 17.14
Evolution and functional impact of rare coding variation from deep sequencing of human exomes. Science (2012) 17.12
The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Gene expression correlates of clinical prostate cancer behavior. Cancer Cell (2002) 16.27
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol (2013) 16.13
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell (2010) 16.12
Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell (2006) 16.05